Navigation Links
Speedus Receives and Appeals Nasdaq Notice
Date:2/2/2010

FREEHOLD, N.J., Feb. 2 /PRNewswire-FirstCall/ -- Speedus Corp. (Nasdaq: SPDE), today announced that on January 28th, 2010 it received notice from Nasdaq, in the form of a staff determination letter, informing the Company that it did not meet the terms of the extension granted to the Company on December 11, 2009 to comply with the stockholders' equity requirement of Marketplace Listing Rule 5550(b) (the "Rule"), which requires the Company to maintain either (1) a minimum of $2.5 million in stockholders' equity; (2) market value of listed securities of $35 million; or (3) net income from continuing operations of $500,000 in the most recently completed fiscal year or two of the last three most recently completed fiscal years.

On February 2, 2010, Speedus submitted an appeal regarding the Nasdaq staff determination by requesting a hearing with the Nasdaq Hearings Panel (the "Panel").  As a result, a hearing has been scheduled for March 11, 2010, at which time the Panel will consider the plan Speedus has developed for regaining and sustaining compliance with the Rule.  The Panel generally issues a decision within 30 to 45 days following a hearing.

While the Panel has the authority to grant the Company up to 180 days from January 28, 2010 to regain compliance with the Rule, there can be no assurance that the Panel will grant the Company's request for continued listing. The Company's securities will continue to be listed on Nasdaq during this appeal process.

About Speedus Corp.

Speedus Corp. (Nasdaq: SPDE) operates through its two majority subsidiaries, Zargis Medical Corp. and Density Dynamics, Inc. Additional information on Speedus Corp. may be obtained at www.speedus.com or by contacting Peter Hodge at 888-773-3669 (ext. 23) or phodge@speedus.com.

Statements contained herein that are not historical facts, including but not limited to statements about the Company's product, corporate identity and focus, may be forward-looking statements that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the Company, including, but not limited to, the continuing development of the Company's sales, marketing and support efforts.

SOURCE Speedus Corp.

RELATED LINKS
http://www.speedus.com

'/>"/>

SOURCE Speedus Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Speedus Corp. Names Stephen X. Graham to Board of Directors
2. Speedus Announces Fourth Quarter and Fiscal 2007 Results
3. Azantis Inc. Receives 2009 NBJ Business Achievement Award From Nutrition Business Journal
4. The Meadows Health Care Center Receives the Award of Excellence from the Ohio Academy of Nursing Homes
5. Dr. Mahaveer Mehta, A Well Known Dermatologist from Dubai, Receives Prestigious 'Hind Rattan Award'
6. MDS Receives U.S. Federal Trade Commission Provisional Regulatory Approval for Sale of MDS Analytical Technologies
7. Case Western Reserve receives $2.8 million to further breast cancer research
8. Stark Receives Accreditation for ESTA's New Code of Practice
9. Haitian Orphanage Receives BPA-Free Baby Bottle Donation from Glendale Company
10. Summit Medical Group Physician Receives Outstanding Performance Award
11. Congo receives help from space after volcano eruption
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... Antonio, TX (PRWEB) , ... February 12, 2016 , ... ... love, as expressed in Blue SKies Buddha, the biography of Rama - Dr. Frederick ... fact a love story, the love of a Buddhist teacher for teaching and helping ...
(Date:2/12/2016)... ... February 12, 2016 , ... The Lymphoma Research ... lymphoma research and serving the lymphoma community through a comprehensive series of education ... Florida’s philanthropic community at its 10th anniversary Fashion Luncheon on Monday, February 8, ...
(Date:2/12/2016)... Middletown, PA (PRWEB) , ... February 12, 2016 , ... ... year’s event will be held in Anaheim, CA at the Anaheim Convention Center. Almost ... they can see new therapy products in action, learn more about their chosen field ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... ... firm announced that nominations have closed for the ISE Southeast Awards 2016. Finalists ... be announced at the ISE® Southeast Executive Forum and Awards Gala on March ...
(Date:2/12/2016)... ... 12, 2016 , ... Every winter, someone is killed, injured or loses a ... Burn Center, part of the Allegheny Health Network, has partnered with Etna Volunteer ... Heaters Need Space” campaign. , “Space Heaters Need Space” aims to bring ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... 12, 2016  Apellis Pharmaceuticals, Inc., today ... million Series D preferred stock financing, co-led ... Capital Group and venBio Global Strategic Fund, ... IB Investment, and Epidarex Capital. The proceeds of ... advance clinical trials in the Company,s ongoing ...
(Date:2/12/2016)... February 12, 2016 ... titled Chronic Inflammation Global Clinical Trials Review, H2, ... the global clinical trials landscape along with top ... Region, Country (G7 & E7), Trial Status, Trial ... reviews top companies involved and enlists all trials ...
(Date:2/11/2016)... , Feb. 11, 2016 The primary ... and future adoption patterns on the usage of liquid ... the following: - Timeframe of liquid biopsy ... ctDNA, cfDNA and Evs—by organization type - Sample inflow ... types: blood, saliva, stool, serum, and so on. - ...
Breaking Medicine Technology: